Literature DB >> 26097599

Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer.

Hai Yu1, Xinghua Wu2, Yonggang Zhang3, Zhihong Jin4, Guoxin Li5, Haiping Zhao4.   

Abstract

Genetic variability of DNA repair mechanisms influences chemotherapy treatment outcome of gastric cancer. We conducted a cohort study to investigate the role of ERCC1-ERCC2 gene polymorphisms in the chemotherapy response and clinic outcome of gastric cancer. Between March 2011 and March 2013, 228 gastric patients who were newly diagnosed with histopathology were enrolled in our study. Genotypes of ERCC1 rs11615, rs3212986, rs2298881 and ERCC2 rs3212986 were conducted by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) assay. We found that individuals carrying TT genotype of ERCC1 rs11615 and CC genotype of ERCC1 rs2298881 were associated with better response to chemotherapy and longer survival time of gastric cancer. Moreover, individuals with AA genotype of ERCC2 rs1799793 were correlated with shorter survival of gastric cancer. In conclusion, ERCC1 rs11615, rs2298881 and ERCC2 rs1799793 polymorphism play an important role in the treatment outcome of gastric cancer.

Entities:  

Keywords:  ERCC1; ERCC2; gastric cancer; overall survival; polymorphism; response to chemotherapy

Mesh：

Substances：

Year:  2015        PMID： 26097599      PMCID： PMC4466986     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN： 1936-2625


  20 in total

1.  Influence of polymorphisms in DNA repair genes XPD, XRCC1 and MGMT on DNA damage induced by gamma radiation and its repair in lymphocytes in vitro.

Authors:  Joanna Rzeszowska-Wolny; Joanna Polanska; Monika Pietrowska; Olena Palyvoda; Joanna Jaworska; Dorota Butkiewicz; Ronald Hancock
Journal:  Radiat Res       Date:  2005-08       Impact factor: 2.841

2.  DNA damage and repair of leukocytes from Fanconi anaemia patients, carriers and healthy individuals as measured by the alkaline comet assay.

Authors:  Anahita Mohseni-Meybodi; Hossein Mozdarani; Sohail Mozdarani
Journal:  Mutagenesis       Date:  2008-10-03       Impact factor: 3.000

Review 3.  Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.

Authors:  Adam Vilmar; Jens Benn Sørensen
Journal:  Lung Cancer       Date:  2008-09-19       Impact factor: 5.705

Review 4.  ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.

Authors:  Ming Yin; Jingrong Yan; Eva Martinez-Balibrea; Francesco Graziano; Heinz-Josef Lenz; Hyo-Jin Kim; Jacques Robert; Seock-Ah Im; Wei-Shu Wang; Marie-Christine Etienne-Grimaldi; Qingyi Wei
Journal:  Clin Cancer Res       Date:  2011-01-28       Impact factor: 12.531

5.  FAN1 acts with FANCI-FANCD2 to promote DNA interstrand cross-link repair.

Authors:  Ting Liu; Gargi Ghosal; Jingsong Yuan; Junjie Chen; Jun Huang
Journal:  Science       Date:  2010-07-29       Impact factor: 47.728

6.  DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy.

Authors:  Li-E Wang; Ming Yin; Qiong Dong; David J Stewart; Kelly W Merriman; Christopher I Amos; Margaret R Spitz; Qingyi Wei
Journal:  J Clin Oncol       Date:  2011-09-26       Impact factor: 44.544

7.  Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy.

Authors:  Zheng-mao Lu; Tian-hang Luo; Ming-ming Nie; Guo-en Fang; Li-ye Ma; Xu-chao Xue; Guo Wei; Chong-we Ke; Jian-wei Bi
Journal:  Tumour Biol       Date:  2013-12-08

8.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

9.  Human DNA repair genes.

Authors:  R D Wood; M Mitchell; J Sgouros; T Lindahl
Journal:  Science       Date:  2001-02-16       Impact factor: 47.728

10.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860
View more
  8 in total

1.  Genetic variability of ERCC1 genes in NER pathway influences the treatment outcome of gastric cancer.

Authors:  Yu Bai; Lei Wang; Guangjun Li; Xiangjie Fang; Yan Li; Shujuan Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy.

Authors:  Rujiao Liu; Xiaoying Zhao; Xin Liu; Zhiyu Chen; Lixin Qiu; Ruixuan Geng; Weijian Guo; Guang He; Jiliang Yin; Jin Li; Xiaodong Zhu
Journal:  Tumour Biol       Date:  2015-08-28

3.  Polymorphisms in DNA repair genes in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome.

Authors:  Gloria Ravegnini; Margherita Nannini; Vittorio Simeon; Muriel Musti; Giulia Sammarini; Maristella Saponara; Lidia Gatto; Milena Urbini; Annalisa Astolfi; Guido Biasco; Maria A Pantaleo; Nicola Venturoli; Patrizia Hrelia; Sabrina Angelini
Journal:  Tumour Biol       Date:  2016-07-27

4.  Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.

Authors:  Juanmei Mo; Min Luo; Jiandong Cui; Shaozhang Zhou
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

5.  Polymorphisms of the DNA Methyltransferase 1 Gene Predict Survival of Gastric Cancer Patients Receiving Tumorectomy.

Authors:  Zhifang Jia; Xing Wu; Donghui Cao; Chuan Wang; Lili You; Meishan Jin; Simin Wen; Xueyuan Cao; Jing Jiang
Journal:  Dis Markers       Date:  2016-03-21       Impact factor: 3.434

6.  ERCC1 rs3212986 A/C polymorphism is not associated with chemotherapy treatment outcomes in gastric cancer patients: evidence from 11 publications in Chinese populations.

Authors:  Weiwei Tang; Hanjin Wang; Yuemei Wang; Xiaowei Wang
Journal:  Onco Targets Ther       Date:  2017-12-20       Impact factor: 4.147

7.  Predictive Value of Two Polymorphisms of ERCC2, rs13181 and rs1799793, in Clinical Outcomes of Chemotherapy in Gastric Cancer Patients: A Meta-Analysis.

Authors:  Mengxi Li; Yan Zhao; Erjiang Zhao; Kunlun Wang; Weiquan Lu; Ling Yuan
Journal:  Dis Markers       Date:  2018-11-19       Impact factor: 3.434

8.  Genetic polymorphisms of ERCC-1 and ERCC-2 are not prognostic markers in osteosarcoma patients with chemotherapy: A meta-analysis in Chinese population.

Authors:  Dabiao Liu; Xuesong Liu
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.